SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim'

PartnershipOpakalimPositive

AI Analysis

Summary

SK Biopharmaceuticals announced an in-license agreement for Opakalim, a near-commercial epilepsy drug candidate, with upfront and milestone payments up to $795M, targeting U.S. commercial launch as early as 2029.

Outcome Details

In-license agreement for near-commercial epilepsy drug candidate

Importance:7/10

Sentiment:

0.70

in-licensingepilepsypartnershipKv7 platformcommercial launch

Related Companies

$SKBP

Read the original article

Published by PR Newswire Pharma on August 26, 2026 9:29 AM

Read Original